Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PURPOSE: Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated improved survival in previously treated patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I, multicohort study, was conducted to explore the s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Rizvi, Naiyer A., Hellmann, Matthew D., Brahmer, Julie R., Juergens, Rosalyn A., Borghaei, Hossein, Gettinger, Scott, Chow, Laura Q., Gerber, David E., Laurie, Scott A., Goldman, Jonathan W., Shepherd, Frances A., Chen, Allen C., Shen, Yun, Nathan, Faith E., Harbison, Christopher T., Antonia, Scott
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2016
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569693/
https://ncbi.nlm.nih.gov/pubmed/27354481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.66.9861
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars